Activated DCs present tumor antigens on MHC I or MHC II molecules to CD8+T cells and CD4+ T cells, respectively, and the body’s antitumor immune effect is ultimately mediated by T lymphocytes (CD8+ cytotoxic T lymphocytes and CD4+ helper T cells) [35,36]. This evidence concerns the gene CD8A and neoplasm.